Prasco Labs Patent-Cliff Exposure & CMS Drug Spending Portfolio

Prasco Labs (US): 13 reconciled FDA prescription therapies, $2.36B 2024 CMS Part D & Medicaid spend, and $900 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies13
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$2.36B
2024 Medicare Part D Spend$1.39B
2024 Medicaid Spend$972.1M
California HCAI SB 17 FilingsSpecialty launch notice ($900 intro WAC)